{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:40:34Z","timestamp":1773272434000,"version":"3.50.1"},"reference-count":53,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T00:00:00Z","timestamp":1579132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The effectiveness of hematopoietic stem cell transplantation (HSCT) for mucopolysaccharidosis type II (MPS II, Hunter disease) remains controversial although recent studies have shown HSCT provides more clinical impact. This study aims to evaluate the long-term effectiveness of HSCT using the activity of daily living (ADL) scores in patients with MPS II. Sixty-nine severely affected MPS II patients (19 patients who received HSCT and 50 untreated patients) and 40 attenuated affected patients (five with HSCT and 35 untreated) were investigated by a simplified ADL questionnaire. The frequency of clinical findings and the scores of ADL (verbal, gross motor, and the level of care) were analyzed statistically. The mean age of onset of 19 severely affected patients who received HSCT was 1.40 years \u00b1 1.06, which is not statistically different from that of 50 untreated patients (p = 0.11). Macroglossia, frequent airway infection, hepatosplenomegaly, joint contracture, and sleep apnea were less frequent in the HSCT-treated group of severe MPS II patients. The severe phenotype HSCT treated group reported a statistically significant higher score of verbal function and gross motor function between the ages of 10 and 15 years and a higher level of care score between 10 and 20 years. Patients with the attenuated phenotype showed high ADL scores, and all of five HSCT treated patients reported a lower frequency of frequent airway infection, coarse skin, umbilical\/inguinal hernia, hepatosplenomegaly, heart valve disorders, and carpal tunnel. In conclusion, HSCT is effective, resulting in improvements in clinical features and ADL in patients with MPS II. HSCT should be re-reviewed as a therapeutic option for MPS II patients.<\/jats:p>","DOI":"10.3390\/diagnostics10010046","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T04:14:41Z","timestamp":1579234481000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of Activity of Daily Life in Mucopolysaccharidosis Type II Patients with Hematopoietic Stem Cell Transplantation"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-2834","authenticated-orcid":false,"given":"Yasuyuki","family":"Suzuki","sequence":"first","affiliation":[{"name":"Medical Education Development Center, Gifu University, Yanagido 1-1, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madeleine","family":"Taylor","sequence":"additional","affiliation":[{"name":"Nemours\/Alfred I. Dupont Hospital for Children, 1600 Rockland Rd., Wilmington, DE 19803, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Orii","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Fukao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadao","family":"Orii","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 501-1194, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-2160","authenticated-orcid":false,"given":"Shunji","family":"Tomatsu","sequence":"additional","affiliation":[{"name":"Nemours\/Alfred I. Dupont Hospital for Children, 1600 Rockland Rd., Wilmington, DE 19803, USA"},{"name":"Department of Pediatrics, Gifu University Graduate School of Medicine, Yanagido 1-1, Gifu 501-1194, Japan"},{"name":"Department of Pediatrics, Thomas Jefferson University, Philadelphia, PA 19107, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,1,16]]},"reference":[{"key":"ref_1","unstructured":"Neufeld, E., and Muenzer, J. (2010). The Online Metabolic Basis of Inherited Disease, McGraw-Hill. The McGraw-Hill Metabolic bases of inherited diseases."},{"key":"ref_2","unstructured":"Tomatsu, S., Kubaski, F., Stapleton, M., Suzuki, Y., Orii, K.O., Vairo, F., Brusius-Facchin, A.C., Leistner-Segal, S., Graeff Burin, M., and Fischender Moura de Souza, C. (2018). Mucopolysaccharidosis Type II: Clinical Features, Biochemistry, Diagnosis, Genetics, and Treatment, Nova Science Publishers."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(81)91046-1","article-title":"Reversal of clinical features of Hurler\u2019s disease and biochemical improvement after treatment by bone-marrow transplantation","volume":"2","author":"Hobbs","year":"1981","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood.V87.11.4894.bloodjournal87114894","article-title":"Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome","volume":"87","author":"Peters","year":"1996","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF00710053","article-title":"Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation","volume":"18","author":"Shapiro","year":"1995","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0022-3476(96)70202-0","article-title":"Bone marrow transplantation in Hunter syndrome","volume":"129","author":"McKinnis","year":"1996","journal-title":"J. Pediatr."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic Stem Cell Transplantation for Patients with Mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/j.bbmt.2016.08.015","article-title":"Allogeneic Hematopoietic Stem Cell Transplantation in Thirty-Four Pediatric Cases of Mucopolysaccharidosis-A Ten-Year Report from the China Children Transplant Group","volume":"22","author":"Wang","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_11","first-page":"62","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_12","first-page":"100455","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/j.bbmt.2019.02.012","article-title":"Hematopoietic Stem Cell Transplantation for Mucopolysaccharidoses: Past, Present, and Future","volume":"25","author":"Taylor","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_14","unstructured":"Tomatsu, S. (2018). Mucopolysaccharidosis type II: Clinical features, biochemistry, diagnosis, genetics, and treatment. Mucopolysaccharidoses Update, Nova Science Publishers."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ymgme.2014.11.002","article-title":"Activities of daily living in patients with Hunter syndrome: Impact of enzyme replacement therapy and hematopoietic stem cell transplantation","volume":"114","author":"Tanjuakio","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"ref_16","first-page":"5","article-title":"Growth charts for patients with Hunter syndrome","volume":"1","author":"Patel","year":"2014","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): A clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","article-title":"The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus","volume":"171","author":"Muenzer","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: A nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bmt.1705970","article-title":"Emerging trends in transplantation of inherited metabolic diseases","volume":"41","author":"Prasad","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"ref_21","unstructured":"(2019, December 12). Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761103s000lbl.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.braindev.2006.08.015","article-title":"Evaluation of ADL in patients with Hunter disease using FIM score","volume":"29","author":"Kato","year":"2007","journal-title":"Brain Dev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1702398","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome)","volume":"25","author":"Peters","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_24","first-page":"433","article-title":"Bone marrow transplantation in a Hunter patient with P266H mutation","volume":"4","author":"Coppa","year":"1999","journal-title":"Int. J. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1023\/A:1005525931994","article-title":"Long-term follow-up following bone marrow transplantation for Hunter disease","volume":"22","author":"Vellodi","year":"1999","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: Outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"key":"ref_27","unstructured":"Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., and Amemiya, A. (2007). Mucopolysaccharidosis Type II. GeneReviews\u00ae, University of Washington."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-0036-1584602","article-title":"Neurodevelopmental Outcome after Hematopoietic Cell Transplantation in Inborn Errors of Metabolism: Current Considerations and Future Perspectives","volume":"47","author":"Boelens","year":"2016","journal-title":"Neuropediatrics"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/BF00219675","article-title":"Mucopolysaccharidosis type II (Hunter disease): 13 gene mutations in 52 Japanese patients and carrier detection in four families","volume":"92","author":"Yamada","year":"1993","journal-title":"Hum. Genet."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/humu.9128","article-title":"Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: Identification of 13 novel mutations","volume":"21","author":"Kim","year":"2003","journal-title":"Hum. Mutat."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/ajmg.a.32781","article-title":"Incidence of the mucopolysaccharidoses in Taiwan, 1984\u20132004","volume":"149","author":"Lin","year":"2009","journal-title":"Am. J. Med. Genet. A"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ymgme.2017.05.016","article-title":"Epidemiology of mucopolysaccharidoses","volume":"121","author":"Khan","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"ref_33","unstructured":"Tomastu, S. (2018). Epidemiology of Mucopolysaccharidoses. Mucopolysaccharidoses Update, Nova Science Publishers."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2009.05.006","article-title":"Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation","volume":"98","author":"Araya","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","article-title":"Japan Elaprase Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)","volume":"99","author":"Okuyama","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1702397","article-title":"Unrelated umbilical cord blood transplantation in infancy for mucopolysaccharidosis type IIB (Hunter syndrome) complicated by autoimmune hemolytic anemia","volume":"25","author":"Mullen","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/pbc.23185","article-title":"Children\u2019s psychological distress during pediatric HSCT: Parent and child perspectives","volume":"58","author":"Chang","year":"2012","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_38","unstructured":"Gelb, M.H., Kumar, A.B., Yi, F., Liu, Y., Chennamanen, N., Masi, S., Elliot, S., Turecek, F., and Scott, C.R. (2018). Newborn Screening for MPS Diseases by Direct Assay of Enzymes in Dried Blood Spots by Tandem Mass Spectrometry, Nova Science Publishers."},{"key":"ref_39","first-page":"647","article-title":"Newborn Screening of Mucopolysaccharidoses: Comparison of Fluorometric technique and Tandem Mass Spectrometry for Enzyme Assay","volume":"Volume 1","author":"Chuang","year":"2018","journal-title":"Mucopolysaccharidoses Update"},{"key":"ref_40","first-page":"661","article-title":"Newborn screening and biomarkers for Mucopolysaccharidoses by GAG assay","volume":"Volume 1","author":"Kubaski","year":"2018","journal-title":"Mucopolysaccharidoses Update"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/bit.21602","article-title":"Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier","volume":"99","author":"Boado","year":"2008","journal-title":"Biotechnol. Bioeng."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","article-title":"Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein","volume":"14","author":"Boado","year":"2017","journal-title":"Mol. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40259-018-0264-7","article-title":"Plasma Pharmacokinetics of Valanafusp Alpha, a Human Insulin Receptor Antibody-Iduronidase Fusion Protein, in Patients with Mucopolysaccharidosis Type I","volume":"32","author":"Pardridge","year":"2018","journal-title":"BioDrugs"},{"key":"ref_44","unstructured":"(2019, December 12). ArmaGen\u2019s AGT-181 Demonstrates Neurocognitive Benefit in Children with Severe MPS I. Available online: http:\/\/armagen.com\/news\/armagens-agt-181-demonstrates-neurocognitive-benefit-children-severe-mps\/."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/mp500258p","article-title":"Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells","volume":"11","author":"Boado","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.molpharmaceut.6b00037","article-title":"Insulin Receptor Antibody-alpha-N-Acetylglucosaminidase Fusion Protein Penetrates the Primate Blood-Brain Barrier and Reduces Glycosoaminoglycans in Sanfilippo Type B Fibroblasts","volume":"13","author":"Boado","year":"2016","journal-title":"Mol. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.ymthe.2018.02.032","article-title":"A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II","volume":"26","author":"Sonoda","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10545-018-0221-0","article-title":"The efficacy of intracerebroventricular idursulfase-beta enzyme replacement therapy in mucopolysaccharidosis II murine model: Heparan sulfate in cerebrospinal fluid as a clinical biomarker of neuropathology","volume":"41","author":"Sohn","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_49","unstructured":"(2019, December 12). Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children with MPS I, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03053089."},{"key":"ref_50","unstructured":"(2019, December 12). A Study to Test the Possibility of Cross Reaction Induced by the Idursulfase Drug to GSK2788723, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT01602601."},{"key":"ref_51","unstructured":"(2019, December 12). A Study of JR-141 in Patients with Mucopolysaccharidosis II, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT03359213."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.ymgme.2017.12.343","article-title":"Anti-drug antibody response in mucopolysaccharidosis type I patients treated with AGT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein","volume":"123","author":"Schmidt","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"ref_53","unstructured":"(2019, December 12). Clinigen, K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-Beta ICV, Hunter Syndrome Drug). Available online: https:\/\/www.prnewswire.com\/news-releases\/clinigen-kk-and-gc-pharma-announce-exclusive-licensing-agreement-in-japan-for-hunterase-idursulfase-beta-icv-hunter-syndrome-drug-300824455.html."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/1\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:05:13Z","timestamp":1760364313000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/1\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,16]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1]]}},"alternative-id":["diagnostics10010046"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10010046","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,16]]}}}